Detalles de la búsqueda
1.
Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study.
BMJ Open
; 11(4): e037457, 2021 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33849844
Resultados
1 -
1
de 1
1
Próxima >
>>